Evaluation of glycoprotein B genotypes and load of CMV infecting blood leukocytes on prognosis of AIDS patients;Avaliação de genótipos de glicoproteína B e carga de CMV de leucócitos no prognóstico de pacientes de Aids

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 53, Issue 2, 2011, Pages 83-88

  Cunha, Aldo Albuquerque ^a   Aquino, Vitor Hugo ^a   Mariguela, Viviane ^a   Nogueira, Maurício Lacerda ^b   Figueiredo, Luiz Tadeu Moraes ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

Author keywords

AIDS; CMV; CMV genotypes; CMV load; HIV

Indexed keywords

GLYCOPROTEIN B; GLYCOPROTEIN B1; GLYCOPROTEIN B2; GLYCOPROTEIN B3; GLYCOPROTEIN B4; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; GLYCOPROTEIN B, SIMPLEXVIRUS; VIRUS ENVELOPE PROTEIN;

ADULT; AIDS PATIENT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FATALITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRESCHOOL CHILD; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION; VIRUS LOAD; AIDS RELATED COMPLEX; GENETICS; POLYMERASE CHAIN REACTION; VIROLOGY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENOTYPE; HUMANS; LEUKOCYTES; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 79955916892     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/s0036-46652011000200005     Document Type: Article

References (29)

1. Aquino VH, Figueiredo LTM. High prevalence of renal transplant recipients infected with more than one cytomegalovirus glycoprotein B genotype. J Med Virol. 2000;61:138-42.
2. Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. J Clin Virol. 2001;22:11-29.
3. Arista S, De Grazia S, Giammanco GM, Di Carlo P, Iannitto E. Human cytomegalovirus glycoprotein B genotypes in immunocompetent, immunocompromised, and congenitally infected Italian populations. Arch Virol. 2003;148:547-54.
4. Bongarts A, Von Laer D, Vogelberg C, Ebert K, Van Lunzen J, Garweg J, et al. Glycoprotein B genotype of human cytomegalovirus: distribution in HIV-infected patients. Scand J Infect Dis. 1996;28:447-9.
5. Chern KC, Chandler DB, Martin DF, Kuppermann BD, Wolitz RA, Margolis TP. Glycoprotein B subtyping of cytomegalovirus (CMV) in the vitreous of patients with AIDS and CMV retinitis. J Infect Dis. 1998;178:1149-53.
6. Chou SW, Dennison KM. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences enconding neutralization-related epitopes. J Infect Dis. 1991;163:1229-34.
7. Cunha AA, Marin LJ, Aquino VH, Figueiredo LTM. Diagnosis of cytomegalovirus infections by qualitative and quantitative PCR in HIV infected patients. Rev Inst Med Trop Sao Paulo. 2002;44:127-32.
8. Deayton JR, Wilson P, Sabin CA, Davey CC, Johnson MA, Emery VC, et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS. 2000;14:1163-70.
9. Drew WL, Chou S, Miner RC, Mohr BA, Busch MP, van der Horst CM, et al. Cytomegalovirus glycoprotein B groups in human immunodeficiency virus-infected patients with incident retinitis. J Infect Dis. 2002;186:114-7.
10. Dunn OJ. Multiple comparisons using rank sums. Technometrics. 1964;6:241-52.
11. Gilbert C, Handfield J, Toma E, Lalonde R, Bergeron MG, Boivin G. Human cytomegalovirus glycoprotein B genotypes in blood of AIDS patients: lack of association with either the viral DNA load in leukocytes or presence of retinitis. J Med Virol. 1999;59:98-103.
12. Goossens VJ, Wolffs PF, van Loo IH, Bruggeman CA, Verbon A. CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in The Netherlands. AIDS. 2009;23:1425-9.
13. Gourlain K, Salmon D, Gault E, Leport C, Katlama C, Matheron S, et al. Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol. 2003;69:401-7.
14. Griffiths PD. CMV as a cofactor enhancing progression of AIDS. J Clin Virol. 2006;35:489-92.
15. Jabs DA, Holbrook JT, Van Natta ML, Clark R, Jacobson MA, Kempen JH, et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 2005;112:771-9.
16. Maniatis T, Jeffrey A, Kleid DG. Nucleotide sequence of the rightward operator of phage lambda. Proc Natl Acad Sci USA. 1975;72:1184-8.
17. Michel D, Marre E, Hampl W, Roczkos J, Müller S, Hertenstein B, et al. Intestinal cytomegalovirus disease in immunocompromised patients may be ruled out by search for cytomegalovirus DNA in stool samples. J Clin Microbiol. 1995;33:3064-7.
18. Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, the transmission of infection from cell to cell, and fusion of infected cells. Virology. 1993;197:143-58.
19. Pellegrin I, Carrigue I, Binquet C, Chene G, Neau D, Bonot P, et al. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J Clin Microbiol. 1999;37:3124-32.
20. Pignatelli S, Dal Monte P, Rossini G, Landini MP. Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Rev Med Virol. 2004;14:383-410.
21. Rasmussen L, Cowan CM. Neutralizing antibody to gB2 human cytomegalovirus does not prevent reactivation in patients with human immunodeficiency virus infection. J Gen Virol. 2003;84:1853-7.
22. Sanchez JL, Storch GA. Multiplex, quantitative, realtime PCR assay for cytomegalovirus and human DNA. J Clin Microbiol. 2002,40:2381-6.
23. Shepp DH, Match ME, Ashraf AB, Lipson SM, Millan C, Pergolizzi R, et al. Cytomegalovirus glycoprotein B groups associated with retinitis in AIDS. J Infect Dis. 1996;174:184-7.
24. Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, Penfold ME, Schall TJ. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol. 2002;76:1285-92.
25. Springer KL, Weinberg A. Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J Antimicrob Chemother. 2004;54:582-6.
26. Steininger C, Puchhammer-Stockl E, Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J Clin Virol. 2006;37:1-9
27. Tarragó D, Quereda C, Tenório A. Different cytomegalovirus glycoprotein B genotype distribution in serum and cerebrospinal fluid specimens determined by a novel multiplex nested PCR. J Clin Microbiol. 2003;41:2872-7.
28. Torok-Storb B, Boeckh M, Hoy C, Leisenring W, Myerson D, Gooley T. Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood 1997;90:2097-102.
29. Yamamoto AY, Figueiredo LTM, Mussi-Pinhata MM. Infecção congênita por citomegalovirus: muito freqüente, mas pouco diagnosticada. J Pedriatr (Rio J). 1999;75:126-30.